MediXall Group
Market Cap
US$194.6m
Last Updated
2019/12/14 01:26 UTC
Data Sources
Company Financials
Executive Summary
MediXall Group, Inc., together with its subsidiaries, operates healthcare marketplace platform in the United States.
Risk Analysis
+ 2 more risks
Snowflake Analysis
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has MediXall Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDXL's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
0%
MDXL
-1.1%
US Healthcare Services
0.6%
US Market
1 Year Return
11.7%
MDXL
26.5%
US Healthcare Services
20.8%
US Market
Return vs Industry: MDXL underperformed the US Healthcare Services industry which returned 26.5% over the past year.
Return vs Market: MDXL underperformed the US Market which returned 20.8% over the past year.
Shareholder returns
| MDXL | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | -1.1% | 0.6% |
| 30 Day | 29.1% | 1.8% | 2.5% |
| 90 Day | n/a | 2.2% | 4.9% |
| 1 Year | 11.7%11.7% | 26.7%26.5% | 23.5%20.8% |
| 3 Year | n/a | 89.2%88.5% | 46.5%37.0% |
| 5 Year | n/a | 64.4%62.9% | 64.6%46.5% |
Price Volatility Vs. Market
How volatile is MediXall Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is MediXall Group undervalued compared to its fair value and its price relative to the market?
985.43x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDXL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDXL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDXL is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: MDXL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDXL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDXL is overvalued based on its PB Ratio (985.4x) compared to the US Healthcare Services industry average (3.9x).
Next Steps
Future Growth
How is MediXall Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
26.7%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MediXall Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of MDXL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MediXall Group's filings and announcements here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has MediXall Group performed over the past 5 years?
-42.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDXL is currently unprofitable.
Growing Profit Margin: MDXL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDXL is unprofitable, and losses have increased over the past 5 years at a rate of -42.4% per year.
Accelerating Growth: Unable to compare MDXL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDXL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-0.2%).
Return on Equity
High ROE: MDXL has a negative Return on Equity (-1394.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is MediXall Group's financial position?
Financial Position Analysis
Short Term Liabilities: MDXL's short term assets ($50.7K) do not cover its short term liabilities ($297.4K).
Long Term Liabilities: MDXL's short term assets ($50.7K) do not cover its long term liabilities ($64.2K).
Debt to Equity History and Analysis
Debt Level: MDXL is debt free.
Reducing Debt: MDXL has not had any debt for past 5 years.
Balance Sheet
Inventory Level: MDXL has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if MDXL's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDXL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MDXL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26% each year
Next Steps
Dividend
What is MediXall Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MDXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MDXL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDXL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDXL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDXL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of MediXall Group's salary, the management and board of directors tenure and is there insider trading?
2.0yrs
Average management tenure
CEO
Neil Swartz (57yo)
3yrs
Tenure
US$150,000
Compensation
Mr. Neil Swartz, CPA, serves as the Interim Chief Executive Officer at MediXall Group, Inc since 2016 and served as its President. Mr. Swartz has been the Interim Chief Executive Officer and Interim Presid ...
Management Age and Tenure
2.0yrs
Average Tenure
57yo
Average Age
Experienced Management: MDXL's management team is considered experienced (2 years average tenure).
Board Age and Tenure
1.8yrs
Average Tenure
60yo
Average Age
Experienced Board: MDXL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.
Management Team
Tim Hart (60yo)
CFO, Treasurer
- Tenure: 7yrs
- Compensation: US$250.00k
Neil Swartz (57yo)
Interim Chief Executive Officer
- Tenure: 3yrs
- Compensation: US$150.00k
Michael Swartz (28yo)
President of Medixall.com
- Tenure: 0.7yrs
Guy Connor (57yo)
Executive Vice President
- Tenure: 0yrs
John Howard
Senior Vice President of Laboratory Services
- Tenure: 1yrs
Board Members
Noel Guillama-Alvarez (60yo)
Chairman of the Board
- Tenure: 3yrs
Tim Hart (60yo)
CFO, Treasurer
- Tenure: 7yrs
- Compensation: US$250.00k
Howard Braverman (72yo)
Member of Strategic Advisory Board
- Tenure: 0.8yrs
Steven Gass
Member of Strategic Advisory Board
- Tenure: 1.3yrs
Winston Marshall (54yo)
Member of Medical Advisory Board
- Tenure: 1.8yrs
John DeLuca
Member of Medical Advisory Board
- Tenure: 1.8yrs
Kenneth Janson
Member of Medical Advisory Board
- Tenure: 1.8yrs
Benjamin Frosch
Member of Strategic Advisory Board
- Tenure: 1.3yrs
Ellis Ellis
Member of Advisory Board
- Tenure: 0.8yrs
Company Information
MediXall Group, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: MediXall Group, Inc.
- Ticker: MDXL
- Exchange: OTCPK
- Founded: 1998
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$194.571m
- Shares outstanding: 75.71m
- Website: https://www.medixall.com
Number of Employees
Location
- MediXall Group, Inc.
- 2929 East Commercial Boulevard
- Suite PH-D
- Fort Lauderdale
- Florida
- 33308
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MDXL | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Dec 2016 |
Biography
MediXall Group, Inc., together with its subsidiaries, operates healthcare marketplace platform in the United States. The company’s cloud- based MediXall.com platform that connects patients with healthcare ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/14 01:26 |
| End of Day Share Price | 2019/12/11 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.